U.S. Hotel and Resort REITs Stock News

Cadence Design Systems recently expanded its collaboration with NVIDIA, integrating its chip and system design software with NVIDIA’s Grace CPUs, Blackwell GPUs and CUDA-X stack to power agentic AI design tools across electronic design, system design and life sciences. A distinctive aspect of this deal is Cadence’s plan to offer turnkey, physics-grounded AI design engines on its Millennium M2000 supercomputer, aiming to support autonomous, long-running engineering workflows in areas ranging...

In recent days, Transense Technologies plc announced it had secured a £2.99 million DriveSense contract, led by Cummins and part-funded by the UK Government, to develop next-generation smart electric drive systems for heavy-duty zero-emission vehicles, while Cummins also expanded its use of Laser Photonics’ CleanTech laser technology in engine maintenance. Together with Cummins’ data center-driven Power Systems strength and ongoing legal and competitive pressures, these developments...

FinVolution Group has reported fourth-quarter 2025 results showing revenue of CNY 3,023.88 million and net income of CNY 424.71 million, alongside full-year 2025 revenue of CNY 13.57 billion and net income of CNY 2.54 billion. The company also lifted its annual dividend to US$0.306 per ADS and set an approximate 50% total payout ratio via dividends and buybacks, underscoring management’s emphasis on returning capital to shareholders. We’ll now examine how FinVolution’s higher dividend and...

If you are wondering whether Wendy's at around US$7.04 is a bargain or a value trap, this article will help you weigh what the current share price might be implying. The stock has faced heavy pressure, with returns of 3.2% over 7 days, 5.9% over 30 days, 13.8% year to date, 51.1% over the past year, and 60.3% and 57.6% over 3 and 5 years respectively. Recent attention on Wendy's has focused on broader questions around its brand position, store footprint and capital allocation. All of these...

In early March 2026, Veeva Systems reported fourth-quarter revenue of US$835.95 million and net income of US$244.2 million, alongside higher full-year revenue of US$3.20 billion and net income of US$908.91 million, and issued guidance calling for continued revenue growth in fiscal 2027. The company also highlighted expanding adoption of its Vault CRM platform and new wins such as AOP Health’s broad use of Veeva’s Development, Quality, Commercial, and Data Clouds, underlining its role as a...

Earlier this month, Applied Materials announced it is working with Micron Technology to co-develop next-generation DRAM, high-bandwidth memory and NAND at Applied’s new US$5.00 billion EPIC Center and Micron’s Boise innovation hub, while Micron separately began sampling a 256GB LPDDR5X SOCAMM2 low-power server memory module for AI data centers. Together with Micron’s recent Taiwan capacity expansion moves, these collaborations and products highlight how the company is tying its technology...

In early March 2026, Simon Property Group reported record Q4 2025 results, with earnings and US$1.79 billion in revenue far above forecasts, launched a US$2.00 billion share repurchase program, and issued 2026 guidance pointing to higher funds from operations and net operating income. Management’s decision to pair a large buyback with plans for disciplined, accretive acquisitions and high-return redevelopments highlights a dual focus on returning capital while reinvesting for longer-term...

Stock performance context for CorMedix Without a specific news catalyst driving fresh headlines, CorMedix (CRMD) continues to draw attention as investors weigh its recent share performance in relation to its role in developing therapies for life threatening conditions. The stock last closed at US$6.54, with returns showing mixed momentum. It recorded a 1.4% gain over the past day, alongside a slight decline over the past week. See our latest analysis for CorMedix. Recent trading tells a mixed...

Event context and recent share performance Ducommun (DCO) has been drawing attention after recent share price moves, with the stock last closing at US$126.91. Over the past month, it shows a 2.4% gain and about 36% in the past 3 months. See our latest analysis for Ducommun. Despite some recent softness, with a 7 day share price return of 3.48%, Ducommun’s 90 day share price return of 35.82% and 1 year total shareholder return of 112.58% point to strong positive momentum. If you are looking...

Board member Raymond A. Link recently sold nearly 25% of his nLIGHT (NasdaqGS:LASR) holdings. The sale came shortly after the company reported record revenue tied to defense focused products. The transaction followed a period of strong momentum in nLIGHT's aerospace and defense laser business. nLIGHT, listed on NasdaqGS:LASR, develops high power semiconductor and fiber lasers used in industrial, aerospace and defense applications. The business has been gaining attention for its defense...

Brown & Brown (BRO) has come onto investors’ radar after a recent share price move, with the stock up around 1% over the past month yet showing a decline over the past three months. See our latest analysis for Brown & Brown. That recent uptick sits within a mixed picture, with the 30 day share price return of 1.05% contrasting with a 90 day share price decline of 14.55% and a 1 year total shareholder return of 41.96% in the red. This suggests momentum has been fading after stronger multi year...

How Albertsons Companies Stock Has Been Trading Recently Albertsons Companies (ACI) has seen a mixed stretch recently, with a modest move over the past week, softer performance over the month, and a slight decline across the past 3 months. See our latest analysis for Albertsons Companies. At a share price of $17.31, Albertsons Companies has seen recent share price pressure, with a 30 day share price return decline of 6.79%, while the 1 year total shareholder return decline of 18.61% contrasts...

NeoGenomics (NEO) has drawn attention after its share price closed at $8.24, with recent returns showing pressure over the past month and past 3 months, prompting investors to reassess the cancer testing specialist. See our latest analysis for NeoGenomics. The recent 1 day share price return of 4.57% comes after a 30 day share price decline of 27.59% and a 1 year total shareholder return of 16.26% in the red. This indicates that pressure has been building for some time rather than momentum...

In early March 2026, Signet Jewelers presented at three major consumer and retail conferences hosted by Citi, Bank of America, and UBS in Florida and New York, sharing updates with institutional investors. These appearances came as the jeweler flagged pressure from higher gold and silver costs and slightly weaker same-store sales toward late 2025, prompting more cautious sentiment around its outlook. We’ll now explore how rising precious metal costs and softer same-store sales readings may...

Earlier in March 2026, Amazon.com, Inc. completed a record multi-currency bond sale, issuing around US$37 billion and several billion euros of senior unsecured notes across maturities ranging from 2028 to 2076 to help finance large-scale AI and cloud data center infrastructure. The size and breadth of this debt issuance, supported by a broad syndicate of global underwriters, underline how central long-term AI and AWS capacity build-out has become to Amazon’s corporate funding strategy. We’ll...

In recent days, Moody's Corporation drew attention by issuing a negative credit outlook for New York City and being caught in broader market concerns after JPMorgan Chase restricted lending to private credit providers, even as Moody's also featured in a new climate‑focused REIT ETF that uses its physical risk models. This mix of heightened municipal and private credit risk concerns alongside the application of Moody's climate analytics to a new ETF underscores how the company sits at the...

Veracyte, Inc. recently appointed Kevin Haas, Ph.D., as its first Chief Development and Technology Officer, tasking him with overseeing end-to-end product development across diagnostic assays, software, bioinformatics and program management to support its expanding global portfolio of laboratory-developed tests and in vitro diagnostic products. This new role, filled by a leader with deep experience in automated lab technology, AI and genomics platforms, underscores Veracyte’s intent to more...

Earlier this month, Averna announced it had partnered with Curtiss-Wright to build five custom aerospace test systems that integrate secure data management and Curtiss-Wright's manufacturing execution systems for precision, safety-critical applications. This collaboration highlights how Curtiss-Wright is leaning on specialist automation expertise to enhance its production capabilities for Tier 1 aerospace programs and demanding defense customers. Next, we'll examine how this new aerospace...

In recent days, The Times’ publication of extracts that prompted a high-profile response from the Duke and Duchess of Sussex concentrated reader attention on royal coverage, while Google faced renewed calls from European publishers including News Corp for EU regulators to conclude a long-running antitrust probe and impose penalties. Together, this surge in engagement around royal news and News Corp’s prominent role in pushing EU scrutiny of Google underscores how its UK media reach and...

Earlier in March 2026, Illumina announced a collaboration with Veritas Genetics Powered By Fuze Health to integrate whole-genome sequencing into preventive healthcare via insurance plans, while also advancing a large-scale multiomic drug discovery effort through its expanded Alliance for Genomic Discovery with Nashville Biosciences and new pharma partners. Together, these initiatives aim to make clinical-grade genomics and proteomics part of routine care and research, creating a large,...

Why Ensign Group is on investors’ radar today Ensign Group (ENSG) has drawn attention after recent share price moves, with the stock showing mixed short term performance alongside stronger gains over the past 3 months and year. See our latest analysis for Ensign Group. At the current share price of $209.46, Ensign Group’s recent 1 day and 1 month share price returns have softened slightly. However, the 90 day share price return of 19.45% and 1 year total shareholder return of 61.61% suggest...

Cboe Global Markets (CBOE) has put fresh attention on its stock with two new product moves: a planned bitcoin volatility index and a new prediction market framework that reshapes outcome-based trading payouts. See our latest analysis for Cboe Global Markets. The latest product announcements come as momentum in the stock has been building, with a 90-day share price return of 15.67% and a 1-year total shareholder return of 34.32%, while multi year total returns remain strong overall. If news...

Solaris Energy Infrastructure recently closed two deals that will add about 900 MW of new natural gas-fueled turbine capacity by 2029, including the acquisition of Genco Power Solutions and the purchase of 30 turbine delivery slots, funded through a mix of cash, new shares, assumed debt, and a new US$300 million credit facility. This expansion program will lift Solaris’s total operated power generation capacity to roughly 3,100 MW by 2029 and commits the company to approximately US$935...

Spyre Therapeutics recently reported that it has completed recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 basket trial evaluating SPY072, an extended half-life TL1A-targeting antibody, and has accelerated the expected timing of topline proof-of-concept data to the third quarter of 2026 for RA and the fourth quarter of 2026 for psoriatic arthritis and axial spondyloarthritis. This progress underscores how basket and platform trial designs could speed clinical...